HOME
COMPANY
Partners
Executive Summary
PEOPLE
Kees Groen, CFO
Victor van Beusechem, CSO
Wenliang Dong, CEO
PIPELINE
Technology
ORCA-010
P53 Functions
RNA Interference
Scientific Publications
HORIZON2020
NEWS
CONTACT
HOME
COMPANY
Partners
Executive Summary
PEOPLE
Kees Groen, CFO
Victor van Beusechem, CSO
Wenliang Dong, CEO
PIPELINE
Technology
ORCA-010
P53 Functions
RNA Interference
Scientific Publications
HORIZON2020
NEWS
CONTACT
technology Archives - ORCA Therapeutics
Recent Posts
ORCA Therapeutics Announces Treatment of First Patient in Phase I/IIa study
ORCA Therapeutics receives approval from Health Canada to initiate a Phase I/IIa study with its oncolytic adenovirus ORCA-010 in treatment-naïve prostate cancer patients.
(no title)
Recent Comments
Archives
February 2020
July 2019
June 2014
Categories
Uncategorized
Meta
Log in
Entries feed
Comments feed
WordPress.org
Recent Comments